The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Carbimazole     ethyl3-methyl-2- sulfanylidene-imidazole-1...

Synonyms: Basolest, Mertiran, TYRAZOL, Thyrostat, Carbimazol, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Neo-Mercazole


Psychiatry related information on Neo-Mercazole


High impact information on Neo-Mercazole


Chemical compound and disease context of Neo-Mercazole


Biological context of Neo-Mercazole


Anatomical context of Neo-Mercazole


Associations of Neo-Mercazole with other chemical compounds


Gene context of Neo-Mercazole

  • The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals [31].
  • The following measurements were made basally and for 6 months after carbimazole treatment: serum free T4, T3, bone-specific alkaline phosphatase (b-ALP), IL-6, IL-8, IL-1beta, tumor necrosis factor-alpha, IL-11, and urinary deoxypyridinoline (Udpd) [32].
  • The mitogen-stimulated cellular IL2 receptor expression, IL2 receptor release, and IL2 production did not differ between patients with or without carbimazole therapy [33].
  • We analyzed the sera from 5 patients who presented with DITP after intake of carbimazole [34].
  • Carbimazole-dependent antibodies showed similar reactivity with platelets carrying the Leu(125) and Val(125) PECAM-1 isoforms, indicating that this polymorphic structure, which is located in the first extracellular domain, is not responsible for the epitope formation [34].

Analytical, diagnostic and therapeutic context of Neo-Mercazole


  1. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. McIver, B., Rae, P., Beckett, G., Wilkinson, E., Gold, A., Toft, A. N. Engl. J. Med. (1996) [Pubmed]
  2. Carbimazole and the autoimmune response in Graves' disease. McGregor, A.M., Petersen, M.M., McLachlan, S.M., Rooke, P., Smith, B.R., Hall, R. N. Engl. J. Med. (1980) [Pubmed]
  3. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Berghout, A., Wiersinga, W.M., Drexhage, H.A., Smits, N.J., Touber, J.L. Lancet (1990) [Pubmed]
  4. Myositis in association with carbimazole therapy. Page, S.R., Nussey, S.S. Lancet (1989) [Pubmed]
  5. Jaundice due to carbimazole. Lunzer, M., Huang, S.N., Ginsburg, J., Ahmed, M., Sherlock, S. Gut (1975) [Pubmed]
  6. Evaluation of olfactory and auditory system effects of the antihyperthyroid drug carbimazole in the Long-Evans rat. Genter, M.B. J. Biochem. Mol. Toxicol. (1998) [Pubmed]
  7. Biopsy-proven myositis with microvasculitis in association with carbimazole. Pasquier, E., Genereau, T., Baudrimont, M., Cabane, J., Biour, M., Imbert, J.C. Lancet (1991) [Pubmed]
  8. Carbimazole and breastfeeding. Rylance, G.W., Woods, C.G., Donnelly, M.C., Oliver, J.S., Alexander, W.D. Lancet (1987) [Pubmed]
  9. Fetal hyperthyroidism: experience of treatment in four siblings. Cove, D.H., Johnston, P. Lancet (1985) [Pubmed]
  10. Excretion of carbimazole and propylthiouracil in breast milk. Low, L.C., Lang, J., Alexander, W.D. Lancet (1979) [Pubmed]
  11. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis. Wall, J.R., Fang, S.L., Kuroki, T., Ingbar, S.H., Braverman, L.E. J. Clin. Endocrinol. Metab. (1984) [Pubmed]
  12. Effect of iopanoic acid on radioiodine therapy of hyperthyroidism: long-term outcome of a randomized controlled trial. Bal, C.S., Kumar, A., Chandra, P. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  13. Influence of thyroid function on theophylline kinetics. Vozeh, S., Otten, M., Staub, J.J., Follath, F. Clin. Pharmacol. Ther. (1984) [Pubmed]
  14. Relapse of Graves' disease after medical therapy: predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels. Wilson, R., McKillop, J.H., Pearson, D.W., Cuthbert, G.F., Thomson, J.A. J. Nucl. Med. (1985) [Pubmed]
  15. Propranolol in the surgical treatment of hyperthyroidism, including severely thyrotoxic patients. Feely, J., Crooks, J., Forrest, A.L., Hamilton, W.F., Gunn, A. The British journal of surgery. (1981) [Pubmed]
  16. Graves disease associated with autoimmune thrombocytopenic purpura. Hofbauer, L.C., Spitzweg, C., Schmauss, S., Heufelder, A.E. Arch. Intern. Med. (1997) [Pubmed]
  17. Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism. Jódar, E., Muñoz-Torres, M., Escobar-Jiménez, F., Quesada, M., Luna, J.D., Olea, N. J. Clin. Endocrinol. Metab. (1997) [Pubmed]
  18. Carbimazole and exercise tolerance in chronic airflow obstruction. Butland, R.J., Pang, J.A., Geddes, D.M. Thorax (1982) [Pubmed]
  19. Dietary intake in thyrotoxicosis before and after adequate carbimazole therapy; the impact of dietary advice. Alton, S., O'Malley, B.P. Clin. Endocrinol. (Oxf) (1985) [Pubmed]
  20. Mitosis in the oesophageal epithelium of rats during chronic antithyroid treatment with carbimazole. Tuffery, A.R., Mobarak, M. J. Endocrinol. (1990) [Pubmed]
  21. A case of carbimazole-induced intrahepatic cholestasis. An immune-mediated reaction? Blom, H., Stolk, J., Schreuder, H.B., von Blomberg-van der Flier, M. Arch. Intern. Med. (1985) [Pubmed]
  22. The placental transfer of propylthiouracil, methimazole and carbimazole. Marchant, B., Brownlie, B.E., Hart, D.M., Horton, P.W., Alexander, W.D. J. Clin. Endocrinol. Metab. (1977) [Pubmed]
  23. Normal suppressive T cell function of Epstein-Barr virus-induced B cell activation in Graves' disease. Kahan, A., Lefloch, J.P., Charreire, J. J. Clin. Endocrinol. Metab. (1987) [Pubmed]
  24. Neutropenia and anaemia due to carbimazole-dependent antibodies. Bux, J., Ernst-Schlegel, M., Rothe, B., Panzer, C. Br. J. Haematol. (2000) [Pubmed]
  25. Carbimazole-induced immune haemolytic anaemia: role of drug-red blood cell complexes for immunization. Salama, A., Northoff, H., Burkhardt, H., Mueller-Eckhardt, C. Br. J. Haematol. (1988) [Pubmed]
  26. Detection of cell-drug (hapten)-antibody complexes by the gel test. Salama, A., Berghöfer, H., Mueller-Eckhardt, C. Transfusion (1992) [Pubmed]
  27. The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients. Skellern, G.G., Knight, B.I., Low, C.K., Alexander, W.D., McLarty, D.G., Kalk, W.J. British journal of clinical pharmacology. (1980) [Pubmed]
  28. Mode of action of carbimazole in Graves' disease. Wise, P.H., Marion, M., Pain, R. Clin. Endocrinol. (Oxf) (1979) [Pubmed]
  29. Graves' disease and coexisting struma ovarii: struma expression of thyrotropin receptors and the presence of thyrotropin receptor stimulating antibodies. Teale, E., Gouldesbrough, D.R., Peacey, S.R. Thyroid (2006) [Pubmed]
  30. Spin echo nuclear magnetic resonance studies on intact erythrocytes: changes in cellular metabolism as a consequence of carbimazole therapy. Reglinski, J., Smith, W.E., Wilson, R., Buchanan, L.M., McKillop, J.H., Thomson, J.A. Clin. Endocrinol. (Oxf) (1992) [Pubmed]
  31. The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals. Wilson, R., McKillop, J.H., Buchanan, L.M., Bradley, H., Smith, W.E., Thomson, J.A. Autoimmunity (1990) [Pubmed]
  32. Serum cytokines in thyrotoxicosis. Siddiqi, A., Monson, J.P., Wood, D.F., Besser, G.M., Burrin, J.M. J. Clin. Endocrinol. Metab. (1999) [Pubmed]
  33. T lymphocyte activation in euthyroid Graves' ophthalmopathy: soluble interleukin 2 receptor release, cellular interleukin 2 receptor expression and interleukin 2 production. Lai, K.N., Leung, J.C., Chow, C.C., Cockram, C.S. Acta Endocrinol. (1989) [Pubmed]
  34. Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a target glycoprotein in drug-induced thrombocytopenia. Kroll, H., Sun, Q.H., Santoso, S. Blood (2000) [Pubmed]
  35. Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism? Lucas, A., Salinas, I., Rius, F., Pizarro, E., Granada, M.L., Foz, M., Sanmartí, A. J. Clin. Endocrinol. Metab. (1997) [Pubmed]
  36. Methimazole has no dose-related effect on the intensity of the intrathyroidal autoimmune process in relapsing Graves' disease. Paschke, R., Vogg, M., Kristoferitsch, R., Aktuna, D., Wawschinek, O., Eber, O., Usadel, K.H. J. Clin. Endocrinol. Metab. (1995) [Pubmed]
  37. Early prediction of hypothyroidism following 131I treatment for Graves' disease. Wilson, R., McKillop, J.H., Black, E., Jenkins, C., Thomson, J.A. European journal of nuclear medicine. (1988) [Pubmed]
WikiGenes - Universities